AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01917578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HE Stain
Description: Procedure:~1. Xylene Ⅰ 60℃ 15-20 minutes~2. Xylene Ⅱ 60℃ 15-20 minutes~3. Alcohol 100% Ⅰ 3-5 minutes~4. Alcohol 100% Ⅱ 3-5 minutes~5. Alcohol 95% Ⅱ 3-5 minutes~6. Alcohol 90% Ⅱ 3-5 minutes~7. Wash in running tap water for 3 minutes~8. Hematoxylin 5-10 minutes~9. Wash in running tap water for 3 minutes~10. Differentiate in 1% acid alcohol for 30 seconds~11. Wash in running tap water for 1 minute~12. Bluing in 0.2% ammonia water for 30-60 seconds~13. Wash in running tap water for 3 minutes~14. Counterstain in eosin Y solution for 30-60 seconds~15. Wash in running tap water for 1 minute~16. Alcohol 90% Ⅱ 2-3 minutes~17. Alcohol 95% Ⅱ 2-3 minutes~18. Alcohol 100% Ⅱ 3-5 minutes~19. Alcohol 100% Ⅱ 3-5 minutes~20. Xylene Ⅲ 5-10 minutes~21. Xylene Ⅳ 5-10 minutes~22. Mounting with neutral resin
Study NCT01917578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CX22
Description: The residual tumor areas are microscopically outlined on each slice by pathologist.
Study NCT01917578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epson V600
Description: 1. Each slice that has been microscopically outlined is scanned by Epson V600.~2. Every image by scanning should be saved as JPG.
Study NCT01917578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: 1. Evaluation of the tumor size by MRI was performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size refers to WHO standards.~3. The images of patients which were scanned by MRI should be burned onto disc for 3d reconstruction.
Study NCT01917578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three-Dimensional Reconstruction
Description: A.Pathological images three-dimensional reconstruction:~1. Pathological images registration is based on skin and shear mark by Photoshop 13.0 software.~2. Residual tumor boundary on Pathological images after registration are outlined and taken three-dimensional reconstruction by 3D-doctor 4.0 software.~3. Observe the shrinkage modes in three-dimensional space.~4. According to WHO standard,the boundaries of all residual tumor images are displayed in one plane and the longest diameter and its longest perpendicular diameter of boundaries are measured in one-dimensional space.~5. According to RECIST standard,the longest diameter of boundaries of residual tumor images in three-dimensional space.~B.MRI images three-dimensional reconstruction:the procedure is similar to Pathological images three-dimensional reconstruction
Study NCT01917578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mammography
Description: 1. Evaluation of the tumor size by mammography is performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size and calcification extent refers to WHO standards.~3. Calcification extent is not only measured in mammography image but also under microscope.
Study NCT01917578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC,TC,TA,CAF,CEF
Description: 1. TAC:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 3 cycles)~2. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 2 cycles)~3. TA:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1(Cycled every 21 days for 2 cycles)~4. CAF:Cyclophosphamide 100 mg/㎡ po days 1-14 + Doxorubicin 30 mg/㎡ iv days 1,8 +5-fluorouracil 500 mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)~5. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)
Study NCT01917578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF
Description: 1. AC-P:Doxorubicin 60 mg/㎡ iv day 1 +Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 14 days for 4 cycles)→ Paclitaxel 175mg/㎡ by 3h iv infusion day 1(Cycled every 14 days for 4 cycles) or Paclitaxel 80mg/㎡ by 1h iv infusion weekly for 12 wks.~2. TEC:Docetaxel 75 mg/㎡ iv day 1 + Epirubicin 75 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 6 cycles)~3. AC:Doxorubicin 60 mg/㎡ in day 1 + Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 21 days for 4 cycles)~4. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 4 cycles)~5. TCH:Docetaxel 75 mg/㎡ iv day 1 + Carboplatin AUC 6 iv day1(Cycled every 21 days for 6 cycles) + Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year.~6. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 6 cycles)
Study NCT00778271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 400mg capsules
Study NCT00778271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 400mg capsules
Study NCT03372083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferosirox was provided in tablet forms of 90, 180 and 360mg. Tablets were crushed in the home environment and administered by sprinkling the full dose on to soft food to be consumed immediately.
Study NCT04133090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous block bone graft
Description: Vertical and horizontal osteotomies were performed by means of a 6-mm diameter separation disc under copious irrigation with saline.The harvested bone graft was immediately placed in sterile saline solution to prevent dehydration. Sharp edges around the block graft were rounded under saline irrigation using a 4-mm round bur. The screw holes were properly made on both the recipient site and the block graft using a 1.3 mm drill. The graft was firmly fixed with 1.3 mm screws and a compatible driver. The periphery of the graft and the underlying gap between the screws and the recipient site, were covered with a mixture of particulate allograft and sterile saline solution to minimize resorption and to improve the adaption of the graft. All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
Study NCT04133090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: i-PRF enriched allograft material+ screw tent pole technique
Description: The i-PRF preparation was performed as follows: the blood sample collected in an 8 ml, non-coated plastic tube without anticoagulant was immediately centrifuged at a protocol of 2700 rpm for 2 min. After centrifugation, the liquid autologous fibrin material which comprised the 1 mL upper layer of the tube was collected, using a disposable syringe. The screw holes were made on the recipient site using a 1.3 mm drill. 7 mm long screws were fixed 2mm or 4mm higher than on the recipient site to provide the desired augmentation distance and stabilized by a compatible driver. i-PRF was mixed with allograft material in a sterile metal box. Polymerization was done in 3 to 5 minutes, then this material was applied to the underlying gap between the screws and the recipient site.All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
Study NCT02162511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34+ cell enrichment and T-cell depletion
Study NCT03884933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile team community mental health services
Description: The intervention focuses on changing mental health care systems to be able to provide community-based mental health care for people with severe mental illness. This will be done through the development and implementation of multidisciplinary community mental health teams (CMHTs) in each of the implementation sites, consisting of at least one nurse, psychiatrist, psychologist, social worker, and peer worker (person with lived experience of a severe mental illness). The structure and delivery method of the community mental health teams is part of an evidence-based service delivery model providing flexible, assertive community mental health teams providing integrated services to people with severe mental illness (SMI) in order to structurally attain their recovery goals, as well as timely and appropriate care in the event of a crisis.
Study NCT04379388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web + text smoking cessation intervention
Description: Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
Study NCT00773981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal vacuum assisted drainage
Description: Treatment with vacuum drainage (VD) is a new method primarily developed for wound therapy. The principle of the method is application of negative pressure on the wound surface with the help of a sponge that is connected to a pump. Sponge dressings should be changed 3 times pr week as long as vacuum therapy is used. If there has been no development of granulation tissue or no shrinking of the cavity in 3 weeks Vacuum therapy can be stopped. Maximum vacuum therapy is 8 weeks.
Study NCT02293811 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analysis
Description: An additional blood sample (10ml) will be taken on the day of hospitalization to achieve the genomic studies in search of mutations in constitutional DNA of circulating lymphocytes and acquired mutations of DNA circulating.~We will use the technique of tissue-microarray to analyze the expression level of P2RX7 both in epithelial cells than in stromal cells inflammatory.~Genotyping will be conducted partly on colonic biopsies and also on blood samples (to demonstrate the feasibility of this technique much less debilitating).
Study NCT02420899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: 10mg/d or 20mg/d,po
Study NCT02908828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calanus oil
Study NCT02908828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo dietary oil
Study NCT00820391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KIDNET
Description: Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
Study NCT00820391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation-Relaxation
Description: a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
Study NCT03778359 — intervention group
Intervention type: DRUG
Intervention: Leuprorelin
Description: This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Leuprorelin.
Study NCT03778359 — intervention group
Intervention type: DEVICE
Intervention: Levonorgestrel
Description: This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Levonorgestrel.
Study NCT03778359 — intervention group
Intervention type: DRUG
Intervention: Dienogest
Description: This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Dienogest.
Study NCT03778359 — intervention group
Intervention type: DRUG
Intervention: Progestins
Description: This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Progestins.
Study NCT01205529 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Procainamide
Description: One time intravenous infusion of Procainamide administered over 30 minutes. Dosage is calculated as 10mg/kg based on subject's ideal body weight.
Study NCT00662714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: oral; initial dose: 3x 0.5mg/d; 2 years
Study NCT00662714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: short-acting Insulin (Actrapid)
Description: initial dose: 3x 0.05E/kg/d, injected; 2 years
Study NCT04352491 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01535157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide/LXS + Ketoconazole
Description: Starting dose is: Fenretinide/LXS 800 mg 4-HPR/m2/day and Ketoconazole 400 mg/day
Study NCT01156181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Embryo transfer without any intervention
Study NCT00560547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta
Description: 120, 200 or 360 micrograms / 4 weeks iv (starting dose)
Study NCT04179032 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab 200 mg/mL will be administered as SC injection in left or right thigh and the abdomen.
Study NCT01388621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)
Description: pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles
Study NCT01388621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin (PLD)
Description: pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles
Study NCT01388621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
Study NCT01388621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
Study NCT01388621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles
Study NCT01388621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles
Study NCT01388621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
Study NCT01388621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
Study NCT01388621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 9 mg/kg/BW d1 q3w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
Study NCT02612116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulverized ticagrelor sublingually
Description: Pulverized ticagrelor (180 mg) administered sublingually
Study NCT02612116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulverized ticagrelor orally
Description: Pulverized ticagrelor (180 mg) administered orally
Study NCT02612116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Integral ticagrelor
Description: Integral ticagrelor (180 mg) administered orally
Study NCT03003832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in electronic health record default for new opioid analgesic prescriptions
Study NCT01493947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 1% cream
Description: Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.
Study NCT01493947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 0.75% cream
Description: Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.
Study NCT01378533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF
Description: epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d\*8cycles
Study NCT02530632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: General anesthesia maintained with intravenous propofol infusion
Study NCT02530632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: General anesthesia maintained with inhalational sevoflurane
Study NCT02530632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia induction
Description: Induce routine of general anesthesia, including propofol 1-3mg/kg, fentanyl 1-3mcg/kg, cisatracurium 0.2-0.3mg/kg.
Study NCT02530632 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia induction
Description: Induce routine of general anesthesia, including propofol 1-3mg/kg, fentanyl 1-3mcg/kg, cisatracurium 0.2-0.3mg/kg.
Study NCT04034433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Handgrip exercise program
Description: Handgrip exercise with a rubber ball 4 weeks before the surgery until 4 weeks after the surgery 20 contractions per minute for a total of 20 minutes each day.
Study NCT01420796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swallowing exercise
Description: Patients will perform oral motor exercises for swallowing muscles for five weeks, four days a week.~This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will make sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
Study NCT01420796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercises
Description: Patients will perform expiratory muscle training. Initial load will be 30% of maximal expiratory pressure which will increase until 75%. This load will be keep until end of training. Patients will made the exercises for 30 minutes with three minutes of training and two of rest.
Study NCT01420796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swallowing and breathing exercises
Description: For five weeks, patients will perform swallowing and breathing exercises that follow: expiratory muscle training and sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
Study NCT02785406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
Study NCT02785406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for suvorexant)
Description: Subjects will receive placebo capsules once daily at 10 PM.
Study NCT02520635 — intervention group
Intervention type: DRUG
Intervention: supra-early TEMODAL® chemotherapy
Study NCT02520635 — intervention group
Intervention type: DRUG
Intervention: standard TEMODAL® chemotherapy
Study NCT02520635 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy 60Gy
Study NCT04171388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg
Description: Azithromycin 500mg (Kern Pharma): 2g (4 tablets) at 2 time points during pregnancy: enrollment (\<=24 weeks gestation), and follow-up ANC at least 4 weeks later
Study NCT04171388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient or Fortified Balanced Energy Protein Supplement
Description: Daily multiple micronutrient (MMN) tablet (Contract Pharmacal Corp) for women with mid-upper arm circumference (MUAC) >=23 cm, OR Daily fortified balanced energy protein (BEP) supplement (DSM South Africa; Faffa Food Products): Fortified corn-soy blend (784 kcal/day) for women with MUAC \<23 cm
Study NCT04171388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet 500 mg
Description: Placebo 500mg (Idifarma): 2g (4 tablets) at 2 time points during pregnancy; enrollment (\<24 weeks gestation), and follow up ANC at least 4 weeks later
Study NCT04171388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet 500 mg
Description: Placebo 500mg (Idifarma): 2g (4 tablets) at 2 time points during pregnancy; enrollment (\<24 weeks gestation), and follow up ANC at least 4 weeks later
Study NCT04171388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Infection Management Package (EIMP)
Description: ENROLLMENT VISIT: Screening for bacteriuria with urine culture, and antimicrobial susceptibility testing; Screening for chlamydia and gonorrhea with Cepheid GeneXpert; Presumptive deworming with albendazole 500mg.~FOLLOWUP TREATMENT VISIT: For women with identified urinary tract infection or asymptomatic bacteriuria, treatment with antibiotics based on antimicrobial susceptibility patterns. For women with identified chlamydia or gonorrhea, treatment of woman (and partner) with appropriate antibiotics. Test of cure sample and retreatment of infection.~Second deworming with albendazole at least 4 weeks after enrollment ANC visit.